The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors
Open accessAbstract
Cannabinoids act at two classical cannabinoid receptors (CB 1 and CB 2), a 7TM orphan receptor and the transmitter‐gated channel transient receptor potential vanilloid type‐1 receptor. Recent evidence also points to cannabinoids acting at members of the nuclear receptor family, peroxisome proliferator‐activated receptors (PPARs, with three subtypes α, β (δ) and γ), which regulate cell differentiation and lipid metabolism. Much evidence now suggests that endocannabinoids are natural activators of PPAR α. Oleoylethanolamide regulates feeding and body weight, stimulates fat utilization and has neuroprotective effects mediated through activation of PPAR α. Similarly, palmitoylethanolamide regulates feeding and lipid metabolism and has anti‐inflammatory properties mediated by PPAR α. Other endocannabinoids that activate PPAR α include anandamide, virodhamine and noladin. Some (but not all) endocannabinoids also activate PPAR γ; anandamide and 2‐arachidonoylglycerol have anti‐inflammatory properties mediated by PPAR γ. Similarly, ajulemic acid, a structural analogue of a metabolite of Δ 9‐tetrahydrocannabinol (THC), causes anti‐inflammatory effects in vivo through PPAR γ. THC also activates PPAR γ, leading to a time‐dependent vasorelaxation in isolated arteries. Other cannabinoids which activate PPAR γ include N‐arachidonoyl‐dopamine, HU210, WIN55212‐2 and CP55940. In contrast, little research has been carried out on the effects of cannabinoids at PPARδ. In this newly emerging area, a number of research questions remain unanswered; for example, why do cannabinoids activate some isoforms and not others? How much of the chronic effects of cannabinoids are through activation of nuclear receptors? And importantly, do cannabinoids confer the same neuro‐ and cardioprotective benefits as other PPAR α and PPAR γ agonists? This review will summarize the published literature implicating cannabinoid‐mediated PPAR effects and discuss the implications thereof. British Journal of Pharmacology (2007) 152, 576–582; doi:10.1038/sj.bjp.0707423; published online 20 August 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 3×
“The eicosanoids 15- deoxy-D-l2,14-prostaglandin J2 and 8(S)-hydroxyeicosatetraenoic acid (8(S)-HETE) interact with PPARs with an EC50 of approximately 500 nM (Kliewer et al., 1997).”
BackgroundFu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodríguez de Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., et al. (2003) · Nature · doi:10.1038/nature01921 · Cited by 1,064
Lo Verme, J., Fu, J., Astarita, G., La Rana, G., Russo, R., Calignano, A., & Piomelli, D. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006353 · Cited by 882
The Biology of Peroxisome Proliferator-Activated Receptors
Ferré, P. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s43 · Cited by 776
Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 697
Matias, I., Gonthier, M.-P., Orlando, P., Martiadis, V., De Petrocellis, L., Cervino, C., Petrosino, S., Hoareau, L., Festy, F., Pasquali, R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2679 · Cited by 656
PPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641
Moreno, S., Farioli-Vecchioli, S., & Cerù, M. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.064 · Cited by 587
Peroxisome proliferator-activated receptor γ in diabetes and metabolism
Rangwala, S. M., & Lazar, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.012 · Cited by 450
Demuth, D. G., & Molleman, A. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.05.055 · Cited by 420
Peroxisome proliferator‐activated receptors in the cardiovascular system
Bishop‐Bailey, D. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703149 · Cited by 363
Guzmán, M., Lo Verme, J., Fu, J., Oveisi, F., Blázquez, C., & Piomelli, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404087200 · Cited by 328
Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α
LoVerme, J., Russo, R., La Rana, G., Fu, J., Farthing, J., Mattace-Raso, G., Meli, R., Hohmann, A., Calignano, A., & Piomelli, D. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111385 · Cited by 316
Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation
Bouaboula, M., Hilairet, S., Marchand, J., Fajas, L., Fur, G. L., & Casellas, P. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.05.032 · Cited by 298
PPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
Hwang, J., Kleinhenz, D. J., Lassègue, B., Griendling, K. K., Dikalov, S., & Hart, C. M. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2004 · Cited by 268
Genetic Analysis of Adipogenesis through Peroxisome Proliferator-activated Receptor γ Isoforms
Mueller, E., Drori, S., Aiyer, A., Yie, J., Sarraf, P., Chen, H., Hauser, S., Rosen, E. D., Ge, K., Roeder, R. G., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206950200 · Cited by 246
Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K., Motoshima, H., Taguchi, T., Sonoda, K., Kukidome, D., et al. (2007) · Circulation Research · doi:10.1161/01.res.0000268411.49545.9c · Cited by 235
O’Sullivan, S. E., Tarling, E. J., Bennett, A. J., Kendall, D. A., & Randall, M. D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.121 · Cited by 183
Self-citationPPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
FIEVET, C., FRUCHART, J., & STAELS, B. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.06.009 · Cited by 182
Rockwell, C. E., Snider, N. T., Thompson, J. T., Vanden Heuvel, J. P., & Kaminski, N. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019117 · Cited by 176
15-Lipoxygenase Metabolism of 2-Arachidonylglycerol
Kozak, K. R., Gupta, R. A., Moody, J. S., Ji, C., Boeglin, W. E., DuBois, R. N., Brash, A. R., & Marnett, L. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201084200 · Cited by 160
Seimandi, M., Lemaire, G., Pillon, A., Perrin, A., Carlavan, I., Voegel, J. J., Vignon, F., Nicolas, J., & Balaguer, P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.06.010 · Cited by 153
Cannabinoids and PPARα signalling
Sun, Y., Alexander, S. P. H., Kendall, D. A., & Bennett, A. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341095 · Cited by 137
Endocannabinoids in adipocytes during differentiation and their role in glucose uptake
Gasperi, V., Fezza, F., Pasquariello, N., Bari, M., Oddi, S., Finazzi‐Agrò, A., & Maccarrone, M. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6445-4 · Cited by 136
Liu, J., Li, H., Burstein, S. H., Zurier, R. B., & Chen, J. D. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.5.983 · Cited by 129
Cimini, A., Benedetti, E., Cristiano, L., Sebastiani, P., D’Amico, M. A., D’Angelo, B., & Loreto, S. D. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.09.043 · Cited by 129
Going nuclear in metabolic and cardiovascular disease
Glass, C. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27913 · Cited by 111
Rockwell, C. E., & Kaminski, N. E. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065524 · Cited by 107
Yan, Z. C., Liu, D. Y., Zhang, L. L., Shen, C., Li, Q., Cao, T. B., Wang, L., Nie, H., Zidek, W., Tepel, M., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.213 · Cited by 106
Molecular basis of selective PPARγ modulation for the treatment of Type 2 diabetes
Gelman, L., Feige, J. N., & Desvergne, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.03.004 · Cited by 98
Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases
Lleo, A., Galea, E., & Sastre, M. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6516-1 · Cited by 93
Astarita, G., Giacomo, B. D., Gaetani, S., Oveisi, F., Compton, T. R., Rivara, S., Tarzia, G., Mor, M., & Piomelli, D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.105221 · Cited by 92
Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer
Fenner, M. H., & Elstner, E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.557 · Cited by 88
PPAR agonists in the treatment of atherosclerosis
Francis, G. A., Annicotte, J.-S., & Auwerx, J. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00014-6 · Cited by 88
Serrano, A., del Arco, I., Pavón, F. J., Macías, M., Perez‐Valero, V., & de Fonseca, F. R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.03.007 · Cited by 79
Ambrosio, A. L. B., Dias, S. M. G., Polikarpov, I., Zurier, R. B., BURSTEIN, S. H., & Garratt, R. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702538200 · Cited by 66
Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects
Rubino, T., Forlani, G., Viganò, D., Zippel, R., & Parolaro, D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03101.x · Cited by 62
Further Characterization of the Time-Dependent Vascular Effects of Δ9-Tetrahydrocannabinol
O’Sullivan, S. E., Kendall, D. A., & Randall, M. D. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095828 · Cited by 61
Self-citationRusso, R., LoVerme, J., Rana, G. L., D’Agostino, G., Sasso, O., Calignano, A., & Piomelli, D. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.007 · Cited by 55
Upham, B. L., Rummel, A. M., Carbone, J. M., Trosko, J. E., Ouyang, Y., Crawford, R. B., & Kaminski, N. E. (2003) · International Journal of Cancer · doi:10.1002/ijc.10899 · Cited by 38
Sun, M., Li, P., Ho, B., et al. (2006) · Biochemical Society Transactions · doi:10.1042/bst20060270 · Cited by 35
Rimonabant in obese patients with type 2 diabetes
Randall, M. D., Kendall, D. A., Bennett, A. J., & O’Sullivan, S. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60265-7 · Cited by 15
Self-citation
Cited by
An Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Molecular Targets of the Phytocannabinoids: A Complex Picture
Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Progress in the Chemistry of Organic Natural Products · doi:10.1007/978-3-319-45541-9_4 · Cited by 454
Metadata
- Authors
- O'Sullivan, S. E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 152
- Issue
- 5
- Pages
- 576-582
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2120367130
- Cited by
- 510
- References
- 43
- FWCI
- 19.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.